#GI25  
OrigAMI-1 readout showing s 22% ORR to amivantamab monotherapy. 

Some real world data of immunotherapy use in MSI-H Colon Cancer showing benefit in patients with peritoneal mets (and more interestingly) significant benefit to primary tumor resection with a HR .44).
#gi25
#GI25